NewLink Genetics Corp (NASDAQ:NLNK)’s algenpantucel-L is expected to garner the highest sales and will be launched in both resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398,” director says. NewLink Genetics Corp (NASDAQ:NLNK) stock performance was -9.03% in last session and finished the day at $24.98. Traded volume was 808,573.00million shares in the last session and the average volume of the stock remained 627.75K shares. NewLink Genetics Corp (NASDAQ:NLNK) insider ownership is 3.70%.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) dropped -5.97 percent to $61.70 Thursday on volume of 954,917.00million shares. The intra-day range of the stock was $60.75 to $66.19. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a market capitalization of $3.94billion.

Kindred Biosciences, Inc. (NASDAQ:KIN) announced the pricing of its public offering of 3,000,000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by Kindred Bio, upsized from the previously announced public offering of $50,000,000. Kindred Biosciences Inc (NASDAQ:KIN)’s stock on Apr 03, 2014 reported a decrease of -8.97% to the closing price of $18.17. Its fifty two weeks range is $8.75 -$26.99. The total market capitalization recorded $294.85million. The overall volume in the last trading session was 1.03million shares. In its share capital, KIN has 16.23million outstanding shares.

Agenus Inc. (NASDAQ:AGEN) today announced that GlaxoSmithKlines (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients, which contains AgenusQS-21 Stimulon® adjuvant, will be stopped. GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. On Thursday, shares of Agenus Inc (NASDAQ:AGEN) dropped -4.67% to close the day at $3.06. Company return on investment (ROI) is -581.40% and its monthly performance is recorded as -38.43%. Agenus Inc (NASDAQ:AGEN) quarterly revenue growth is 10.07%.